Literature DB >> 19400302

Novel bifunctional peptides as opioid agonists and NK-1 antagonists.

Padma Nair1, Takashi Yamamoto, Vinod Kulkarni, Sharif Moye, Edita Navratilova, Peg Davis, Tally Largent, Shou-Wu Ma, Henry I Yamamura, Todd Vanderah, Josephine Lai, Frank Porreca, Victor J Hruby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19400302      PMCID： PMC5632931          DOI： 10.1007/978-0-387-73657-0_235

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  6 in total

1.  Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties.

Authors:  Iwona Maszczynska Bonney; Stacy E Foran; James E Marchand; Andrzej W Lipkowski; Daniel B Carr
Journal:  Eur J Pharmacol       Date:  2004-03-19       Impact factor: 4.432

2.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Authors:  P J Horan; A Mattia; E J Bilsky; S Weber; T P Davis; H I Yamamura; E Malatynska; S M Appleyard; J Slaninova; A Misicka
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

3.  N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists.

Authors:  A M MacLeod; K J Merchant; M A Cascieri; S Sadowski; E Ber; C J Swain; R Baker
Journal:  J Med Chem       Date:  1993-07-09       Impact factor: 7.446

4.  Spinal neurons that possess the substance P receptor are required for the development of central sensitization.

Authors:  Sergey G Khasabov; Scott D Rogers; Joseph R Ghilardi; Christopher M Peters; Patrick W Mantyh; Donald A Simone
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

5.  Inhibition of neurokinin-1-substance P receptor and prostanoid activity prevents and reverses the development of morphine tolerance in vivo and the morphine-induced increase in CGRP expression in cultured dorsal root ganglion neurons.

Authors:  Kelly J Powell; Remi Quirion; Khem Jhamandas
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

6.  Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.

Authors:  Takashi Yamamoto; Padma Nair; Peg Davis; Shou-wu Ma; Edita Navratilova; Sharif Moye; Suneeta Tumati; Josephine Lai; Todd W Vanderah; Henry I Yamamura; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2007-05-22       Impact factor: 7.446
  6 in total
  3 in total

1.  Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2015-06-15       Impact factor: 2.823

2.  Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Authors:  Padma Nair; Takashi Yamamoto; Tally M Largent-Milnes; Scott Cowell; Vinod Kulkarni; Sharif Moye; Edita Navratilova; Peg Davis; Shou-Wu Ma; Todd W Vanderah; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-07-02       Impact factor: 2.823

3.  In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera.

Authors:  Karel Guillemyn; Patrycja Kleczkowska; Alexandre Novoa; Bart Vandormael; Isabelle Van den Eynde; Piotr Kosson; Muhammad Faheem Asim; Peter W Schiller; Mariana Spetea; Andrzej W Lipkowski; Dirk Tourwé; Steven Ballet
Journal:  Mol Brain       Date:  2012-01-30       Impact factor: 4.041
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.